Pipecuronium
Arduan (pipecuronium) is a small molecule pharmaceutical. Pipecuronium was first approved as Arduan on 1990-06-26.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| berinert | Biologic Licensing Application | 2009-11-10 |
| cinryze | Biologic Licensing Application | 2010-11-01 |
| covaryx | unapproved drug other | 2020-01-25 |
| covaryx covaryx | unapproved drug other | 2013-02-26 |
| eemt | unapproved drug other | 2020-01-22 |
| eemt eemt | unapproved drug other | 2013-03-01 |
| esterified estrogens and methyltestosterone | unapproved drug other | 2025-02-10 |
| esterified estrogens and methyltestosterone full strength esterified estrogens and methyltestosterone half strength | unapproved drug other | 2025-03-10 |
| esterified estrogens and methytestesterone | unapproved drug other | 2022-11-25 |
| estratest f.s. | unapproved drug other | 2024-09-06 |
Show 18 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Coronary disease | D003327 | — | — | — | — | — | — | 1 | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 1 | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
| Low cardiac output | D002303 | — | — | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Delayed emergence from anesthesia | D055191 | — | — | — | — | — | — | 1 | 1 |
| Neuromuscular monitoring | D061886 | — | — | — | — | — | — | 1 | 1 |
| Pneumoperitoneum | D011027 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pipecuronium |
| INN | pipecuronium bromide |
| Description | Pipecuronium bromide is a steroid ester. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives: neuromuscular blocking agents; quaternary ammonium derivatives: neuromuscular blocking agents |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 68399-58-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201206 |
| ChEBI ID | 8230 |
| PubChem CID | 65332 |
| DrugBank | — |
| UNII ID | R6ZTY81RE1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 256,723 documents
View more details
Safety
Black-box Warning
Black-box warning for: Covaryx, Covaryx covaryx, Eemt, Eemt eemt, Esterified estrogens and methyltestosterone, Esterified estrogens and methyltestosterone full strength esterified estrogens and methyltestosterone half strength, Esterified estrogens and methytestesterone, Estratest f.s., Estratest f.s. estratest h.s., Estratest fs estratest hs, Menest, Omega-3 rx complete, Omega-3 well pack
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use